Titan Pharmaceuticals Inc (TTNP)

[Doctor Detroit]

Parkinson’s

From Zacks

“We estimate that 80% of the PD population in the US will be candidates for implantable ropinirole and that Titan or its partner will be able to achieve 1% penetration into this market in 2020, the first full year of launch. Eventually, we estimate that ropinirole implant will be able to achieve a terminal market share of 10% by 2025.”

Couple of points:

--The first full year of launch is 2020, which means approval in 2019.

--The US Parkinson’s market is about 1 million people, so 80% of that is 800,000. 1% of that = 8,000, and 10% = 80,000.

-Zacks estimates a $6,000 annual cost of treatment for ropinirole (after reserving 15% for sales related costs, returns, etc).

- 2020 = 8,000 x $6,000=$48 million. 2025 =80,000 x $6,000 =$480 million.